Benchmark Holdings
Ticker: BMK Exchange: AIM www.benchmarkplc.com

Benchmark helps deliver improved healthcare products and welfare services to the global aquaculture and livestock industries. Rising demand from clients for its products and services to manage sustainability practice and performance underlines BMK's opportunity for significant organic and external growth.

FY24 results: refocus post disposal

Benchmark Holdings reported FY24 revenue from continuing operations of £90.4m, -13%YoY (currency adjusted, CER, -6%YoY), and (adj.) EBITDA of £11.9m, -30%YoY (CER: -24%YoY reflecting the decline in revenue in the Health business (-57%YoY) and changes in Advanced Nutrition product mix. Net debt was reduced from £65.5m in FY23 to £49.0m due to the impact of the discontinued Genetics business removing debt related to the Saltern facility. The focus is now on the structure of operations post sale of the Genetics business area, streamlining the organisation and reducing costs.

Post-divestment our revenue and (adj.) EBITDA outlook is determined principally by two factors: trends in the overall market for shrimp (demand and prices), and contribution from the Health business based on Salmosan®Vet revenue streams, in FY25 respectively £86.7m and £12.7m, and for FY26, £90.9m and £14.0m. We reinstate our fair value at 43p/share, to be reviewed on completion of the disposal process as details of the use of proceeds, structure of the balance sheet and proposals for further restructuring emerge. Our revised Fair Value, based on a 5-year DCF, is inclusive of a return of capital to shareholders which we estimate at £158m, to be paid in FY25 (£128m) and FY27 (£30m).

 

 

 
Download as a PDF file
26810392321 - benchmark-holdings
Return to Benchmark Holdings

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates